乐观
$183.84
情景价格
$125.540
-3.490 (-2.78%)收盘时
Oracle Corporation offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. The Company operates through three businesses: cloud and license, hardware and service. Its cloud and license business is engaged in the sale, marketing and delivery of its enterprise applications and infrastructure technologies through cloud and on-premise deployment models including its cloud services and license support offerings, and its cloud license and on-premise license offerings. Its hardware business provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management and other hardware-related software to support diverse IT environments. Its services business provides services to customers and partners to help maximize the performance of their investments in Oracle applications and infrastructure technologies.
Oracle Corp is not a good buy right now due to its current price of $128.23, which is significantly down 34.48% year-to-date and 53.74% over the past year. The RSI is at 34.316, indicating oversold conditions, but the negative trend in gross margin, which has decreased to 62.97%, raises concerns about profitability. Additionally, the company faces a high debt burden, with a CDS spread approaching 300 basis points, indicating market skepticism about its financial stability.
Freedom Broker
$205
2026-09-14
Freedom Broker
2026-09-14
目标价
$205
BMO Capital
$195
2026-09-11
BMO Capital
2026-09-11
目标价
$195
UBS
$250
2026-09-11
UBS
2026-09-11
目标价
$250
RBC Capital
$165
2026-09-11
RBC Capital
2026-09-11
目标价
$165
Stifel
$200
2026-09-11
Stifel
2026-09-11
目标价
$200
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Oracle's Growth Potential Amid AI Infrastructure Boom

Zuckerberg Commits to Staying in California for Eight Years Amid Wealth Tax Concerns

Zuckerberg's New Stock Plan to Stay in California Amid Tax Concerns

France's Debt Crisis Alarm Intensifies Amid Rising Default Risks

Elon Musk Invests $1 Billion in Skydance
Oracle Corporation offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. The Company operates through three businesses: cloud and license, hardware and service. Its cloud and license business is engaged in the sale, marketing and delivery of its enterprise applications and infrastructure technologies through cloud and on-premise deployment models including its cloud services and license support offerings, and its cloud license and on-premise license offerings. Its hardware business provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management and other hardware-related software to support diverse IT environments. Its services business provides services to customers and partners to help maximize the performance of their investments in Oracle applications and infrastructure technologies. It operates in the Technology sector (SERVICES-PREPACKAGED SOFTWARE industry).
Oracle Corp is not a good buy right now due to its current price of $128.23, which is significantly down 34.48% year-to-date and 53.74% over the past year. The RSI is at 34.316, indicating oversold conditions, but the negative trend in gross margin, which has decreased to 62.97%, raises concerns about profitability. Additionally, the company faces a high debt burden, with a CDS spread approaching 300 basis points, indicating market skepticism about its financial stability.
36 analysts cover ORCL: 26 rate it Buy, 9 Hold and 1 Sell. The average price target is 309.59.



AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes Partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner. $AZN $ORCL
展开
$ORCL is starting to look very enticing on the weekly chart! The $110-125 support area would be an excellent spot to build a long term position (or common shares) as this area has been respected four times in the last two years! The GEX Heatmap shows the stock surrounded by negative Gamma with the King Node at $145 for October 30th! 👀
展开
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。